Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

4503 Background: Transurethral resection of bladder tumor (TURBT) plus systemic therapy
has been known for decades to achieve durable bladder-intact survival in a subset of …

PURPOSE Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC)
is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the …

439 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) in MIBC improves
survival which correlates with pathologic response (PaR) at radical cystectomy (RC). The …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

PURPOSE To evaluate the safety and efficacy of gemcitabine and cisplatin in combination
with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical …

Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity
and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first …

Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant
metastatic disease. Over the past three decades, perioperative cisplatin-based …

Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of
care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin …

Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic
urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin …